Image Place holder

Heather Sook Han, MD


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Richard M. Schulze Family Foundation Outpatient Center at McKinley Campus
Overview

Cancer Types Treated: Breast Cancer, Ductal Carcinoma In Situ , Inflammatory Breast Cancer , Invasive Ductal Carcinoma , Triple Negative Breast Cancer

Dr. Heather Han is the Research Director and medical oncologist in the Moffitt Cancer Center Department of Breast Oncology. She is dedicated to helping find a cure for the millions of women whose lives have been affected by a diagnosis of breast cancer. Dr. Han finds that Moffitt Cancer Center offers a unique health care environment in that outstanding physicians in every discipline work together for a common cause in the battle against cancer.  She believes that the future of cancer is to provide personalized treatment for every patient.  Moffitt’s Total Cancer Care initiative is making great strides toward this goal. Dr. Han is currently researching outcomes among breast cancer patients of different nationalities, including Asian, African American, Hispanic and Caucasian, to determine whether race may have an impact on disparities in chemotherapy toxicity.  She is also a principal investigator for phase one and phase two clinical trials evaluating novel targeted breast cancer therapies designed to improve prognosis, reduce side-effects and improve quality of life.  Dr. Han enjoys the opportunity to participate in Moffitt’s medical oncology fellowship program, serving as an instructor and mentor for the outstanding medical oncologists of the future.

Education & Training

Board Certification:

  • Medical Oncology
  • Hematology
  • Internal Medicine

Fellowship:

  • University of Miami/Jackson Memorial Hospital - Hematology/Oncology

Residency:

  • Cleveland Clinic Foundation - Internal Medicine

Medical School:

  • Seoul University College of Medicine - MD
Participating Trials

CLINICAL TRIAL 18862
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); SGN-LIV1A; Trastuzumab; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18810
Phase 1b Study To Assess The Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole Or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (Mbc)
Condition: Breast
Intervention: 772256 (Palbociclib); Faslodex (fulvestrant); Femara (Letrozole); Gedatolisib; Letrozole; PF-05212384 (Gedatolisib); Palbociclib; fulvestrant
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 16664
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Metastatic and Locally Advanced Breast Cancer
Condition: Breast
Intervention: Adriamycin (doxorubicin); Taxol (paclitaxel); Triciribine (TCN-PM (0002)); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 19394
An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2-Negative, Brca-Mutant Breast Cancer Patients
Condition: Breast
Intervention: Niraparib
Open

CLINICAL TRIAL 19603
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); SGN-LIV1A
Open

CLINICAL TRIAL 18979
Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Olaparib (Lynparza)
Open

CLINICAL TRIAL 18356
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18386
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Condition: Breast
Intervention: Not Applicable
Open

CLINICAL TRIAL 18621
A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast
Intervention: Adriamycin (doxorubicin); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 19340
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Condition: Breast
Intervention: Herceptin (Trastuzumab); Not Applicable; Placebo; Trastuzumab; Tucatinib; Xeloda (capecitabine); capecitabine; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: Not Applicable; TSR-033; TSR-042
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 19393
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage,Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Condition: Breast
Intervention: Abemaciclib; LY2835219 (Abemaciclib)
Open

CLINICAL TRIAL 19337
A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer
Condition: Breast
Intervention: DC1 Vaccine; Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab; Taxotere (docetaxel); Trastuzumab; carboplatin; docetaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Nktr-214 And In combination With Nktr-214 Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); NKTR-214; NKTR-262; Nivolumab
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition: Multiple
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19105
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)
Condition: Breast
Intervention: AMP-514 (Durvalumab); Durvalumab; Hiltonol poly IC:LC; MEDI4736 (Durvalumab); Montanide ISA 720 VG; PVX-410
Open

CLINICAL TRIAL 19228
A Phase 2, Multi-Center, Open Label Study of NIR178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin lymphoma
Condition: Thoracic
Intervention: NIR178; Not Applicable; PDR001
Open

CLINICAL TRIAL 19462
An Open-Label, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors and Lymphomas
Condition: Multiple
Intervention: Bay 1895344
Open

CLINICAL TRIAL 19632
A Phase Ib/II, Open-Label, Multicenter,Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab; Cobimetinib; Eribulin Mesylate; Gemzar (gemcitabine); Ipatasertib; Not Applicable; SGN-LIV1A; Xeloda (capecitabine); capecitabine; gemcitabine
Open

CLINICAL TRIAL 18825
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Condition: Multiple
Intervention: XMT-1522
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); NKTR-214; Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun;169(2):391-396. Pubmedid: 29392582.
  • Ahmed KA, Grass GD, Orman AG, Liveringhouse C, Montejo ME, Soliman HH, Han HS, Czerniecki BJ, Torres-Roca JF, Diaz R. Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. Int J Breast Cancer. 2018 Jun;2018:6729802. Pubmedid: 29984003. Pmcid: PMC6015692.
  • Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2018 Jan;29(1):154-161. Pubmedid: 29045554. Pmcid: PMC5834075.
  • Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, Antonia S. A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer. Oncotarget. 2018 Feb;9(11):10110-10117. Pubmedid: 29515795. Pmcid: PMC5839376.
  • Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Res Treat. 2018 Apr;168(2):357-364. Pubmedid: 29198055.
  • Reich RR, Lengacher CA, Alinat CB, Kip KE, Paterson C, Ramesar S, Han HS, Ismail-Khan R, Johnson-Mallard V, Moscoso M, Budhrani-Shani P, Shivers S, Cox CE, Goodman M, Park J. Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. J Pain Symptom Manag. 2017 Jan;53(1):85-95. Pubmedid: 27720794.
  • Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol. 2017 Feb;13(4):307-320. Pubmedid: 27739325. Pmcid: PMC5618936.
  • Chow LW, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CY, Loo WT, Glück S, Toi M. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Asia Pac J Clin Oncol. 2017 Dec;13(6):372-378. Pubmedid: 28371190.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Rosa M, Han HS, Ismail-Khan R, Allam-Nandyala P, Bui MM. Beta-catenin Expression Patterns in Matched Pre- and Post-Neoadjuvant Chemotherapy-Resistant Breast Cancer. Ann Clin Lab Sci. 2015 Jan;45(1):10-16. Pubmedid: 25696004.
  • Malo TL, Lipkus I, Wilson T, Han HS, Acs G, Vadaparampil ST. Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting. J Cancer Epidemiol. 2012 Aug;2012:941495. Pubmedid: 22927848. Pmcid: PMC3425834.
  • Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer. 2011 Nov;47(17):2537-2545. Pubmedid: 21741825.
  • Lee MC, Gray J, Han HS, Plosker S. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control. 2010 Jul;17(3):162-172. Pubmedid: 20664513.
  • Biagioli MC, Harvey M, Roman E, Raez LE, Wolfson AH, Mutyala S, Han HS, Markoe A. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Nov;69(4):1067-1073. Pubmedid: 17967302.
  • Han H, Rybicki L, Thiel K, Kalaycio M, Sobecks R, Advani A, Brown S, Sekeres M. White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leuk Lymphoma. 2007 Aug;48(8):1561-1568. Pubmedid: 17701588.